These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
660 related articles for article (PubMed ID: 21894752)
1. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752 [TBL] [Abstract][Full Text] [Related]
2. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490 [TBL] [Abstract][Full Text] [Related]
5. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928 [TBL] [Abstract][Full Text] [Related]
6. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
7. [Mobilization of autologous peripheral blood stem cells by combined chemotherapy and rhG-CSF]. Shi H; Gu X; Zhu L Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):159-61. PubMed ID: 11783025 [TBL] [Abstract][Full Text] [Related]
8. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931 [TBL] [Abstract][Full Text] [Related]
9. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
10. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794 [TBL] [Abstract][Full Text] [Related]
11. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
13. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433 [TBL] [Abstract][Full Text] [Related]
14. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
16. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502 [TBL] [Abstract][Full Text] [Related]
17. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889 [TBL] [Abstract][Full Text] [Related]
18. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692 [TBL] [Abstract][Full Text] [Related]
19. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264 [TBL] [Abstract][Full Text] [Related]
20. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]